



ASX ANNOUNCEMENT

Lumos Diagnostics Board Changes

MELBOURNE, Australia (12 October 2026) – Lumos Diagnostics Holdings Ltd (ASX:LDX, “Lumos” or the “Company”), a leader in rapid, point-of-care diagnostic technologies, is pleased to announce the appointment of Mr Aizaz Syed as a Non-Executive Director effective today. Mr Syed will succeed Mr Lawrence Mehren, who has advised the Board that he will not stand for re-election at the Annual General Meeting (“AGM”) and therefore resigns with effect from today.

Mr Syed represents Tenmile Ventures Pty Ltd (“Tenmile”), Lumos' largest shareholder, and brings extensive experience in healthcare investing, corporate strategy and business growth. He has worked closely with a range of innovative healthcare and life sciences companies, supporting their strategic development.

While Mr Mehren steps down from the Board, he will remain actively involved with Lumos on a consulting basis. Mr Mehren will contribute to the internal Lumos Quarterly Business Review Meeting and support the Company’s management team with their U.S. commercialisation efforts through the application of his extensive diagnostics and commercial experience.

Commenting on the Board transition, Lumos Chairman, Mr Sam Lanyon said, *“We are delighted to welcome Aizaz to the Lumos Board. His extensive healthcare and investment experience, strategic perspective and understanding of innovative life sciences businesses will be valuable as Lumos advances its commercial strategy. We also welcome the perspective he brings as a representative of Tenmile, our largest shareholder.”*

“On behalf of the Board, I would also like to thank Lawrence for his significant contribution to Lumos and the guidance and expertise he has provided during an important period for the Company. We are pleased that Lawrence has agreed to remain available to Lumos in a consulting capacity, enabling us to retain the benefit of his practical industry experience and network relationships as we progress our commercialisation efforts in the U.S.”

Mr Syed’s appointment is effective from the date of this announcement, and in accordance with the Company’s Constitution and the ASX Listing Rules will be put forth for election as a director by shareholders at the forthcoming AGM in November 2026.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Haley Chartres – Australia

HACK Director

haley@hck.digital

+61 423 139 163

Investor Contact:

George Kopsiaftis

IR Specialist, IR Department

ir@lumosdiagnostics.com

+61 409 392 687

Company Registered Office:

Lumos Diagnostics Holdings Ltd

Suite 2, Level 11

385 Bourke Street

Melbourne VIC 3000

info@lumosdiagnostics.com

+61 3 9087 1598